logo
NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial

NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial

Yahooa day ago

-- Pre-specified analyses show that obicetrapib treatment leads to statistically significant and clinically meaningful reductions in the primary outcome measure of Alzheimer's disease biomarker in both the full ITT population (p<0.002) and in ApoE4 carriers (p=0.0215), supporting the emerging link between CETP-inhibition and prevention of AD pathology --
-- NewAmsterdam to present results during the AAIC conference in July --
NAARDEN, The Netherlands and MIAMI, June 09, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or 'NewAmsterdam' or the 'Company'), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ('CVD') with elevated low-density lipoprotein cholesterol ('LDL-C'), for whom existing therapies are not sufficiently effective or well-tolerated, today announced positive topline data from prespecified Alzheimer's Disease ('AD') biomarker analyses in the Phase 3 BROADWAY clinical trial (NCT05142722).
The pivotal Phase 3 BROADWAY study was primarily designed to evaluate the low-density lipoprotein cholesterol ('LDL-C') lowering efficacy of obicetrapib in adult patients with established atherosclerotic cardiovascular disease ('ASCVD') and/or heterozygous familial hypercholesterolemia ('HeFH'), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy. As part of this pivotal registration trial for lowering LDL-C, a pre-specified sub-study was conducted to assess the effect of obicetrapib on plasma biomarkers of AD in both the full study population and in patients carrying the ApoE4 gene.
'These findings strongly support a potential preventive strategy for Alzheimer's disease,' said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam Pharma. 'In this study obicetrapib, a potent CETP inhibitor, improved the progression of key plasma biomarkers of AD pathology over a 12-month period in patients with ASCVD. These data further differentiate obicetrapib and underscore the critical role CETP inhibition may have in mitigating the risk of AD progression, alongside the significant cardiovascular benefits obicetrapib has shown in our pivotal Phase 3 trials.'
The AD sub-study results from BROADWAY build on genetic, Mendelian randomization, and NewAmsterdam's pre-clinical data and data from its Phase 2a clinical proof of concept trial. 'These findings have significant implications for AD prevention, especially for the over 25% of the population that carries one or two ApoE4 risk alleles and who currently lack FDA-approved prevention options,' said Philip Scheltens, professor emeritus at Amsterdam University Medical Center. 'The ability to reduce pathological biomarker progression suggests a potential to alter disease trajectory in this population, thereby delaying or preventing the onset of symptoms. The established safety profile of obicetrapib, demonstrated across multiple large clinical trials, combined with its oral administration, may greatly facilitate clinical implementation.'
'These results are the culmination of over two decades of dedicated scientific research. Approximately two thirds of patients with Alzheimer's disease carry the ApoE4 risk isoform that is associated with a much greater risk of developing AD, and the data shared today support our belief that CETP inhibition and specifically raising small functional HDL particles offers a novel and targeted approach to reducing that risk,' said John Kastelein, M.D., Ph.D., FESC, Chief Scientific Officer of NewAmsterdam. 'When viewed alongside the totality of evidence generated to date, including improvements in LDL-C, small LDL particles, Lipoprotein (a), and key biomarkers associated with diabetes and renal function, these novel data on the prevention of AD-associated pathology further strengthen obicetrapib's profile as a uniquely differentiated therapy with the potential to address multiple interrelated drivers of chronic cardiometabolic disease and neurodegeneration.'
The Company plans to present the full results from the AD sub-study analysis in a Developing Topics oral presentation at the Alzheimer's Association International Conference in Toronto at the end of July 2025.
Design of the Pivotal Phase 3 BROADWAY Clinical Trial
The 52-week, global, pivotal, Phase 3, randomized, double-blind, placebo-controlled multicenter trial evaluated the efficacy and safety of 10 mg obicetrapib compared to placebo as an adjunct to maximally tolerated lipid-lowering therapies in patients with ASCVD and/or HeFH whose LDL-C is not adequately controlled. The trial was conducted at sites in North America, Europe, Asia and Australia. A total of 2,530 patients were randomized 2:1 to receive 10 mg obicetrapib or placebo dosed as a once-daily oral treatment, with or without food for 52 weeks. The mean baseline LDL-C for enrolled patients in the obicetrapib arm was approximately 100 mg/dL despite high intensity statin use reported by nearly 70% of patients during screening. Females comprised approximately 34% of the trial population and the median age of participants at baseline was 65 years.
The primary endpoint was LS mean percent change from baseline in LDL-C of obicetrapib 10 mg compared to placebo after 84 days which showed a reduction of 33% with imputation. Secondary endpoints also included percent changes from baseline of obicetrapib 10 mg compared to placebo in ApoB, Lp(a), ApoA1, HDL-C, non-HDL-C, total cholesterol, and triglycerides at day 84, and on LDL-C levels at days 180 and 365. Other exploratory outcome measures included time from randomization until the first confirmed occurrence of MACE in the obicetrapib arm compared to placebo. The trial also evaluated the safety and tolerability profile of obicetrapib.
Alzheimer's Sub-Study Trial
In BROADWAY, a pre-specified AD sub-study was designed to assess plasma AD biomarkers in patients enrolled in the BROADWAY trial and evaluated the effects of longer duration of therapy (12 months) with a prespecified population of ApoE3/4 or 4/4 carriers. The sub-study included 1727 patients, including 367 ApoE4 carriers. The primary outcome measure was p-tau217 absolute and percent change over 12 months. Additional outcome measures included neurofilament light chain ('NFL'), glial fibrillary acidic protein ('GFAP'), p-tau181, and Aβ42/40 ratio absolute and percent change over 12 months. NewAmsterdam observed statistically significant lower absolute changes in p-tau217 compared to placebo over 12 months in both the full ITT population (p<0.002) and in ApoE4 carriers (p=0.0215).
Design of the Phase 2a Alzheimer's Trial
The open-label and single-arm trial was designed to assess the pharmacodynamics, pharmacokinetics, safety and tolerability of obicetrapib 10 mg in early AD patients carrying at least one copy of ApoE4. A total of 13 patients were given 10 mg obicetrapib and followed for 24 weeks. NewAmsterdam observed reductions in the levels of 24- and 27-hydroxycholestrol in both plasma and cerebrospinal fluid. Overall, obicetrapib was observed to be well-tolerated. No serious adverse events ('AEs') were reported, nor were any AEs considered to be related to the study drug.
About Obicetrapib
Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company's Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company's Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company.
About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
Forward-Looking Statements
Certain statements included in this document that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'should,' 'would,' 'plan,' 'predict,' 'potential,' 'seem,' 'seek,' 'future,' 'outlook' and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the Company's business and strategic plans, the Company's commercial opportunity, the therapeutic and curative potential of the Company's product candidate, the Company's clinical trials and the timing for enrolling patients, the timing and forums for announcing data, the achievement and timing of regulatory approvals, and plans for commercialization. These statements are based on various assumptions, whether or not identified in this document, and on the current expectations of the Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to the approval of the Company's product candidate and the timing of expected regulatory and business milestones, including potential commercialization; whether topline, initial or preliminary results from a particular clinical trial will be predictive of the final results of that trial and whether results of early clinical trials will be indicative of the results of later clinical trials, or whether projections regarding clinical outcomes will reflect actual results in future clinical trials or clinical use of our product candidate, if approved; the potential for varying interpretation of the AD sub-study results; ability to negotiate definitive contractual arrangements with potential customers; the impact of competitive product candidates; ability to obtain sufficient supply of materials; global economic and political conditions, including the Russia-Ukraine and Israel-Hamas conflicts; the effects of competition on the Company's future business; and those factors described in the Company's public filings with the Securities and Exchange Commission. Additional risks related to the Company's business include, but are not limited to: uncertainty regarding outcomes of the Company's ongoing clinical trials, particularly as they relate to regulatory review and potential approval for its product candidate; risks associated with the Company's efforts to commercialize a product candidate; the Company's ability to negotiate and enter into definitive agreements on favorable terms, if at all; the impact of competing product candidates on the Company's business; intellectual property related claims; the Company's ability to attract and retain qualified personnel; and ability to continue to source the raw materials for the Company's product candidate. If any of these risks materialize or the Company's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that the Company does not presently know or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect the Company's expectations, plans, or forecasts of future events and views as of the date of this document and are qualified in their entirety by reference to the cautionary statements herein. The Company anticipates that subsequent events and developments may cause the Company's assessments to change. These forward-looking statements should not be relied upon as representing the Company's assessment as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon the forward-looking statements. Neither the Company nor any of its affiliates undertakes any obligation to update these forward-looking statements, except as may be required by law.
Company ContactMatthew PhilippeP: 1-917-882-7512matthew.philippe@newamsterdampharma.com
Media ContactSpectrum Science on behalf of NewAmsterdamJaryd LeadyP: 1-856-803-7855jleady@spectrumscience.com
Investor ContactPrecision AQ on behalf of NewAmsterdamAustin MurtaghP: 1-212-698-8696austin.murtagh@precisionaq.com

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Syntiant to Demonstrate Ultra-Low-Power Automotive AI Innovations at AutoSens and InCabin 2025
Syntiant to Demonstrate Ultra-Low-Power Automotive AI Innovations at AutoSens and InCabin 2025

Business Upturn

time23 minutes ago

  • Business Upturn

Syntiant to Demonstrate Ultra-Low-Power Automotive AI Innovations at AutoSens and InCabin 2025

IRVINE, Calif., June 10, 2025 (GLOBE NEWSWIRE) — Syntiant Corp., the recognized leader in low-power edge AI deployment, today announced it will showcase two of its vehicle sensing technologies at AutoSens and InCabin 2025, June 10-12 at Huntington Place in Detroit (Booth #210). Syntiant's multimodal automotive solutions are designed to enhance vehicle safety and user experiences by enabling always-on audio and vision intelligence at the edge, without draining the battery or relying on cloud connectivity. Live demonstrations will include: Low-power camera security system . Ideal for applications such as parked vehicle monitoring and fleet management, this AI perimeter security solution keeps dash or external cameras in an ultra-low-power standby mode while continuously monitoring for specific audio or visual cues, such as footsteps, voices or motion near the vehicle. Upon detection, the system instantly activates high-resolution cameras to begin recording at under 200 mW, preserving energy while improving real-time incident capture. In contrast, traditional always-on security systems can draw over 100 watts , limiting them to electric vehicles with large batteries. Syntiant's solution delivers comparable performance at a fraction of the power, enabling always-on security for virtually any vehicle. . Ideal for applications such as parked vehicle monitoring and fleet management, this AI perimeter security solution keeps dash or external cameras in an ultra-low-power standby mode while continuously monitoring for specific audio or visual cues, such as footsteps, voices or motion near the vehicle. Upon detection, the system instantly activates high-resolution cameras to begin recording at under 200 mW, preserving energy while improving real-time incident capture. In contrast, traditional always-on security systems can draw over 100 watts limiting them to electric vehicles with large batteries. Syntiant's solution delivers comparable performance at a fraction of the power, enabling always-on security for virtually any vehicle. External sound detection using vibration sensors. Traditional microphones placed outside of a vehicle are prone to failure in harsh environments. Rain, dust, snow and even car washes might permanently damage the device. Syntiant's V2S vibration sensors mounted on a vehicle's door, windshield or trunk, detect motions caused by external sounds, enabling features like emergency vehicle detection and hands-free voice commands (e.g., 'open trunk'), without the exposure-related limitations of conventional microphones. By effectively turning the vehicle's surface into the microphone, the Syntiant V2S provides a durable and reliable alternative for external sound detection. 'Enhanced sensing capabilities are essential to meet the demands of smarter vehicles, especially when driving conditions are less than ideal,' said Greg Doll, SVP and GM of Syntiant's sensors business unit. 'By integrating sensors, AI hardware and software, we have developed low-power automotive intelligence that can enable vehicles to be more responsive to their surroundings, and ultimately more useful to drivers and passengers.' Syntiant's complete automotive solutions are powered by a combination of its Neural Decision Processors, ML models, sensors and microphones. These technologies power a broad range of intelligent automotive features, including voice and siren detection, blind spot alerts, facial recognition, battery management, in-cabin monitoring and other Advanced Driver Assistance Systems (ADAS). More information about Syntiant's automotive solutions can be found at AutoSens and InCabin 2025 OEMs and Tier 1 suppliers can register at no cost by visiting Partners, including distributors, representatives and design partners, are eligible for a 30% discount, available upon request by emailing [email protected]. To schedule a private demo or meeting with Syntiant (Booth #210), please contact [email protected]. About Syntiant Founded in 2017 and headquartered in Irvine, Calif., Syntiant® is Making Edge AI a Reality™ by delivering highly efficient processor, sensor and software solutions. With more than 100 million purpose-built silicon and ML models deployed, along with billions of MEMS microphones and sensors, Syntiant's technology is powering edge AI applications for speech, audio, sensor and vision processing worldwide. From earbuds to automobiles, the company's turnkey solutions enable advanced edge AI capabilities across diverse consumer and industrial use cases. More information on the company can be found by visiting or by following Syntiant on X @Syntiantcorp or LinkedIn. Media Contact: George Medici/Natalie MuPondelWilkinson Inc. [email protected] or [email protected] 310-279-5968

Ontario, Canada Filtration Manufacturer Camfil Demonstrates Significant Cost Savings for Ontario School Air Filtration Systems
Ontario, Canada Filtration Manufacturer Camfil Demonstrates Significant Cost Savings for Ontario School Air Filtration Systems

Business Upturn

time23 minutes ago

  • Business Upturn

Ontario, Canada Filtration Manufacturer Camfil Demonstrates Significant Cost Savings for Ontario School Air Filtration Systems

Toronto, Ontario, June 10, 2025 (GLOBE NEWSWIRE) — Camfil Canada, a leading provider of commercial and industrial air filtration solutions, today announced the publication of a comprehensive case study demonstrating substantial cost savings achieved through advanced air filter implementation in Ontario school facilities. The research highlights how Canadian educational institutions can reduce operational expenses while improving indoor air quality for students and staff. Addressing Canadian School Air Quality Challenges Ontario schools face unique air quality management challenges, including extreme seasonal temperature variations, budget constraints, and increasing focus on student health and improving the learning environment. The new case study provides a detailed analysis of how proper air filter selection and implementation can address these challenges while delivering measurable financial benefits. 'Canadian schools operate under significant budgetary pressures while maintaining responsibility for student and staff health,' said Joshua Gutherie, Air Quality Expert at Camfil Canada. 'Our case study demonstrates that investing in high-efficiency air filtration technology delivers both improved air quality and substantial cost savings for Ontario schools.' Documented Cost Savings in Ontario Educational Facilities The published case study presents a detailed financial analysis of implementing the plan for Ontario schools, including: ● Energy Cost Reductions: Quantified savings in heating and cooling expenses through improved HVAC system efficiency ● Maintenance Cost Decreases: Reduced filter replacement frequency and HVAC system maintenance requirements ● Extended Equipment Life: Protection of HVAC systems leading to deferred capital replacement costs ● Operational Efficiency Improvements: Streamlined maintenance procedures and reduced labour requirements The study specifically addresses the impact of Ontario's energy costs and seasonal operational demands on the performance and economics of school air filtration systems. Supporting Student Health and Learning Outcomes Beyond cost savings, the case study documents improvements in indoor air quality that directly benefit student health and academic performance. Research continues to demonstrate the connection between improved air quality and enhanced learning environments, making air filtration investments valuable from both financial and educational perspectives. 'Ontario schools are increasingly recognizing that air quality investments support both fiscal responsibility and educational excellence,' noted Guthrie. 'Our case study provides the data and analysis that school boards need to make informed decisions about air filtration technology.' Advanced Filtration Solutions for Canadian Schools The case study features a detailed analysis of air filtration technologies specifically suited to Canadian educational environments, including: ● High-Efficiency Particulate Filters: Engineered to handle Ontario's seasonal allergen and particulate loads while minimizing energy consumption ● Extended Service Life Filters: Designed to maintain performance despite challenging Canadian environmental conditions. This includes fewer replacements, with some filters lasting up to a year in Ontario schools, compared to three months for competing filters. ● Energy-Efficient Filter Media: Optimized for Canadian HVAC systems and operations ● Each solution addresses the specific requirements of Ontario schools, including compliance with provincial building codes, accommodating extreme temperature variations, and optimizing energy cost savings. Practical Implementation Guidance for Ontario School Boards The published case study provides actionable implementation strategies for Ontario educational facilities, addressing common concerns, including: ● Budget Planning: ROI calculations and payback period analysis for different filter upgrade scenarios ● Seasonal Considerations: Implementation of timing recommendations for Ontario school operational schedules ● Maintenance Training: Guidance for school staff on optimizing filter performance and longevity ● Compliance Requirements: Alignment with Ontario building codes and educational facility standards Supporting Ontario's Educational Infrastructure The case study reflects Camfil Canada's commitment to supporting Ontario's educational sector through practical air quality solutions that address both health and financial priorities. As Ontario schools continue to focus on creating optimal learning environments while managing operational costs, evidence-based air filtration strategies provide measurable benefits. The research also addresses emerging considerations for Ontario schools, including enhanced focus on indoor air quality following public health awareness campaigns and increasing emphasis on energy efficiency in public buildings. Canadian Educational Resource Availability The complete Ontario schools air filtration case study is available now through Camfil Canada's website at The resource includes downloadable implementation guides, cost calculation tools, and technical specifications specifically developed for Canadian educational facilities. About Camfil Canada Ontario, Canada Filtration Manufacturer Camfil Camfil Canada is a leading provider of air filtration solutions for commercial, industrial, and institutional applications across Canada. With comprehensive experience in Canadian building environments, the company provides engineered solutions for challenging air quality requirements, including educational facilities, healthcare institutions, commercial buildings, and industrial operations. The company maintains distribution and service capabilities across Canada, providing technical support, installation guidance, and maintenance services from coast to coast. Camfil Canada is part of the global Camfil Group, recognized worldwide for innovation in air filtration technology and commitment to clean air solutions. For more information about Camfil Canada's educational facility air filtration solutions, visit the Camfil Canada Website or contact the Canadian educational applications team at 905-660-0688. Media Contact: Phillip Ilijevski Camfil Canada Inc. Phone: 437-929-1161 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.

Lucasys Income Tax Suite Launches on SAP® Store
Lucasys Income Tax Suite Launches on SAP® Store

Business Upturn

time23 minutes ago

  • Business Upturn

Lucasys Income Tax Suite Launches on SAP® Store

By GlobeNewswire Published on June 10, 2025, 22:29 IST ATLANTA, June 10, 2025 (GLOBE NEWSWIRE) — Lucasys, a leading cloud software and service provider for rate-regulated utilities, today announced that its suite of tax applications – including Lucasys Tax Depreciation, Deferred Tax, TBBS, and Copilot – is now available on the SAP® Store, the digital marketplace for SAP and partner offerings. This milestone follows Lucasys' recent partnership within the SAP® PartnerEdge® Open Ecosystem. By integrating with SAP S/4HANA® and other SAP solutions, these applications provide a seamless experience for customers managing complex tax and regulatory requirements. 'Bringing Lucasys Tax applications to the SAP Store underscores our commitment to fostering innovation and flexibility for utilities and asset-intensive businesses,' said Daniel Chang, Chief Operating Officer at Lucasys. 'With this integration, customers can enhance their SAP environments with modern, purpose-built tax solutions that simplify processes, improve compliance, and unlock actionable insights.' Lucasys' tax applications are designed to streamline and automate critical tax processes, including tax depreciation and deferred tax management, while delivering unparalleled usability and security. The modular architecture and deep regulatory support of these solutions ensure that customers can adapt to changing industry demands and achieve long-term operational excellence. Key Features of the Lucasys Income Tax Suite: Integrated Tax Applications: Single integrated experience across tax applications used for tax accounting, tax compliance, and tax forecasting. Enhanced Usability: Simplified workflows reduce the data maintenance burden for end users and facilitate onboarding and training. Flexible Reporting: Robust, user-driven reporting allows for greater visibility and data confidence. Data-Driven Insights: Provides actionable analytics to facilitate strategic tax planning. Scalable Solutions: Tailored for large enterprises and asset-intensive organizations. To learn more about Lucasys' solutions and their availability in the SAP Store, visit and SAP® Store. About Lucasys Lucasys provides software and technology-enabled services to empower finance, accounting, and tax professionals in asset-intensive industries to optimize the financial performance of their fixed assets and proactively meet changing regulatory and compliance requirements. With a core focus on rate-regulated utilities, Lucasys provides the industry and domain expertise utilities require to meet their business objectives. To learn more about Lucasys, visit A photo accompanying this announcement is available at Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store